Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (CRSP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

- Led by new investor EcoR1 Capital and SR One with participation from existing and new investors - - Well positioned to execute on our on-going clinical trials in oncology, cardiovascular and diabetes, and further accelerate our auto-immune and in vivo gene writing programs - - Further strengthens balance sheet with pro forma cash position >$2.1 billion - ZUG, Switzerland and BOSTON, Feb. 13, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it has entered into an investment agreement for the sale of approximately $280 million of its common shares (the “Shares”) to a select group of institutional investors in a registered direct offering, at a price per share of $71.50, representing a premium of greater than 10% to CRISPR Therapeutics' 30-day volume-weighted average price. The financing is expected to close on or about February 27, 2024, subject to customary closing conditions.

CRISPR Therapeutics Announces $280 Million Registered Direct Offering

— Over 8,000 patients 12 years of age and older with severe SCD or TDT may be eligible for treatment —

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease (SCD) and Transfusion-Dependent Beta Thalassemia (TDT)

Coinbase

UiPath

Roku

Block

Tesla

Zoom Video

Wood's Ark Invest portfolio owns a large number of stocks but isn't as diversified as it might seem. Ark Invest's top holdings include a biotech stock, a crypto stock, a fintech stock, two AI stocks, and more.

Cathie Wood Has 37% of Her Ark Invest Portfolio Invested in These 7 Stocks

Abbott Labs

Vertex Pharmaceuticals

The health sector has two things to offer: new ideas and consistent returns. As a result, healthcare stocks will continue to be a good choice for investors looking for growth opportunities in 2024.

3 Groundbreaking Healthcare Stocks to Buy for Robust Gains

Intuitive Surgical

CRISPR Therapeutics' recent regulatory approval should be the first of others to come. Intuitive Surgical has a long runway despite recent headwinds from weight-loss medicines.

2 Healthcare Stocks to Buy Hand Over Fist in February

Ginkgo Bioworks Holdings

Recursion Pharmaceuticals

Cathie Wood has been investing in a few advanced biotechs lately. She's displaying particular interest in automation-heavy biotechs.

Cathie Wood Just Bought These 3 Biotech Stocks. Should You?

Roblox

Cathie Wood's innovation-packed portfolio may not be suitable for older investors, but those with a multidecade horizon could benefit from owning some of her top picks. CRISPR Therapeutics and Roblox are two of her holdings that stand out as stellar buy-and-hold vehicles.

2 Cathie Wood Stocks I Plan on Buying for My Kids' Portfolios

Teladoc

CRISPR Therapeutics recently reached a major milestone: the approval of its first product. Teladoc Health is taking steps to optimize efficiency and travel the path to profitability.

Got $100? 2 Top Cathie Wood Stocks to Buy and Hold.

In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $64.75, denoting a +0.12% change from the preceding trading day.

CRISPR Therapeutics AG (CRSP) Rises But Trails Market: What Investors Should Know

Illumina

Healthcare stocks are one part of the stock market that has a lot of room to grow until 2024. The healthcare industry is growing because of the growing focus on health and well-being around the world.

Top Stock Picks 2024: 3 Healthcare Stocks Leading Medical Advancements

CRISPR Therapeutics recently won approval for its first product, a potential blockbuster. The company expects to report clinical trial data from its immuno-oncology program this year.

Is CRISPR Therapeutics a Buy in the New Bull Market?

Affirm

ANSYS

MongoDB

With the recent uptrend in large-cap stocks, as reflected by the performance of the SPDR S&P 500 ETF Trust NYSEARCA: SPY, many stocks with top revenue and earnings growth rates are flashing bullish technical signals.

These 5 growth stocks are now in buy ranges

CRISPR Therapeutics' leading candidate recently received regulatory approval. This gene-editing therapy stands to improve the biotech's financial results.

Where Will CRISPR Therapeutics Be in 5 Years?

CRISPR Therapeutics just had its biggest collaborator pull out of a joint program. At the same time, management is cruising for business development opportunities.

1 Setback and 1 Opportunity for CRISPR Therapeutics Stock

Gene therapy will get its share of the spotlight in the medical sector in 2024. The FDA approval for Casgevy, Vertex Pharmaceuticals Inc. NASDAQ: VRTX and CRISPR Therapeutics AG NASDAQ: CRSP CRISPR/Cas9-based treatment for sickle cell disease (SCD) in December 2023 kicked off the gene-editing revolution and mainstream attention.

2 gene editing stocks to keep on your 2024 watchlist

The FDA approved Casgevy, a CRISPR/Cas9 gene-edited therapy, for transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older last week. The market has reacted negatively to the approval, causing a drop in stock prices for Vertex and Crispr Therapeutics, the drug's co-developers. Casgevy faces limitations such as a complex and expensive treatment process, safety concerns, and competition from other gene therapies.

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

CRISPR Therapeutics reached three milestones in recent times and is on its way to product revenue. The biotech company is also making progress with other pipeline programs based on its cutting-edge gene editing technology.

Could CRISPR Therapeutics Stock Help You Become a Millionaire?

Intellia Therapeutics

Intellia Therapeutics is well capitalized, and moving into late-stage clinical trials. CRISPR Therapeutics will be raking in revenue and likely launching another therapy.

Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics

Eli Lilly

Novo Nordisk

CRISPR Therapeutics stock has room to run higher with the biotech's first therapy on the market. Eli Lilly is now the world's biggest drugmaker and has multiple growth drivers.

3 High-Flying Stocks That Could Soar Even More in 2024

Photronics

Zscaler

In the tech space, certain tech stocks stand as front-liners of innovation and strategic brilliance. This article delves into the riveting strategies of three companies that have not merely weathered the storms of their respective industries, but have charted unprecedented courses of triumph.

3 Under-the-Radar Tech Stocks With 250% Growth Potential by 2026

The Food & Drug Administration has approved a second indication for a drug developed using a gene editing process called CRISPR. Casgevy, initially authorised in December for sickle cell disease treatment, the groundbreaking gene therapy is now also sanctioned for treating transfusion-dependent beta-thalassemia.

CRISPR-derived drug gets green light for second indication

The Food and Drug Administration approved the use of Casgevy, a therapy from Vertex Pharmaceuticals and CRISPR Therapeutics that uses CRISPR gene-editing to treat the serious blood disorder transfusion-dependent beta thalassemia—marking the second major U.S. regulatory approval for the emerging gene-editing technology.

FDA Approves New CRISPR Gene-Editing Treatment

Crispr won its second gene-editing approval on Tuesday — two months ahead of time. But CRSP stock slipped, and VRTX stock rose minimally.

Crispr Wins Its Second Gene-Editing Approval In Another Boost To Vertex Stock

- Approximately 1,000 patients in the U.S. 12 years of age and older are now eligible for this one-time treatment- ZUG, Switzerland and BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved CASGEVY™ (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9 gene-edited cell therapy, for the treatment of transfusion-dependent beta thalassemia (TDT) in patients 12 years and older. “We are pleased with the approval of CASGEVY in TDT well ahead of the PDUFA date,” said Samarth Kulkarni, Ph.D.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Transfusion-Dependent Beta Thalassemia

News for CRISPR Therapeutics Stock (CRSP)